74733-24-7

Basic information

• Product Name: Methyl 4-formyl-3-methoxybenzoate
• Synonyms: Benzoic acid, 4-formyl-3-methoxy-, methyl ester;4-Formyl-3-methoxy-benzoicacidmethylester
• CAS NO: 74733-24-7
• Molecular Formula: C₁₀H₁₀O₄
• Molecular Weight: 194.184
• Mol File: 74733-24-7.mol

Chemical Properties

• Boiling Point: 332.3±27.0 °C(Predicted)
• Appearance: /
• Density: 1.191±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: Methyl 4-formyl-3-methoxybenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 4-formyl-3-methoxybenzoate(74733-24-7)
• EPA Substance Registry System: Methyl 4-formyl-3-methoxybenzoate(74733-24-7)

Safety Data

• Hazardous Substances Data: 74733-24-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 4-formyl-3-methoxybenzoate is used as a key intermediate in the synthesis of RORγ inhibitors. These inhibitors are important for the development of drugs targeting RORγ, a nuclear receptor protein that plays a role in various immune and inflammatory responses. By inhibiting RORγ, these drugs can potentially treat autoimmune diseases, chronic inflammation, and other related conditions.
Used in Chemical Synthesis:
Methyl 4-formyl-3-methoxybenzoate is also used as a versatile building block in the synthesis of various organic compounds, particularly those with potential applications in the pharmaceutical, agrochemical, and materials science industries. Its unique functional groups allow for further chemical modifications and the creation of novel molecules with desired properties.

Upstream product

• 619-12-5 4-formyl-3-hydroxybenzoic acid 
• 74-88-4 methyl iodide 
• 56256-14-5 4-bromo-3-methoxy-benzoic acid 
• 67-68-5 dimethyl sulfoxide 
• 24589-98-8 methyl 4-formyl-3-hydroxybenzoate 
• 79236-97-8 methyl 4-(acetoxymethyl)-3-methoxybenzoate 
• 3556-83-0 methyl 4-methyl-3-methoxybenzoate 
• 144-55-8 sodium hydrogencarbonate 
• 70264-94-7 methyl 4-(bromomethyl)-3-methoxybenzoate 
• 79236-96-7 2-methoxy-4-(hydroxymethyl)-3-methoxybenzoate 

Downstream Products

• 188244-70-4 2-(1-hydroxy-2-methoxy-4-methoxycarbonylbenzyl)-1-methyl-6-nitro-4-oxo-1,4-dihydroquinoline 
• 593267-72-2 4-(6-fluoro-1H-indol-3-ylmethyl)-3-methoxy-benzoic acid methyl ester 
• 241498-69-1 4-(6-chloro-1H-indol-3-ylmethyl)-3-methoxy-benzoic acid methyl ester 
• 107786-36-7 4-[5-nitro-1H-indol-3-ylmethyl]-3-methoxy-benzoic acid methylester 
• 1173177-01-9 methyl 3-methoxy-4-(oxazol-5-yl)benzoate 
• 1578190-67-6 3-methoxy-4-(oxazol-5-yl)benzoic acid 
• 1610874-32-2 3-methoxy-N-(3-methoxybenzyl)-4-(oxazol-5-yl)benzamide 
• 102362-00-5 4-Cyano-3-methoxybenzoic acid 
• 1402049-25-5 tert-butyl 4-(6-(2-(2-methoxy-4-(methoxycarbonyl)phenyl)-4-oxothiazolidin-3-yl)pyridin-3-yl)piperazine-1-carboxylate 
• 1402345-15-6 3-methoxy-4-[(E)-3-oxo-3-(2-phenylamino-pyridin-3-yl)-propenyl]-benzoic acid methyl ester 
• 1402345-19-0 3-(4-carboxy-2-methoxy-benzyl)-4-oxo-1-phenyl-1,4-dihydro-[1,8]naphthyridine-2-carboxylic acid methyl ester 
• 1402345-18-9 3-(2-methoxy-4-methoxycarbonyl-benzyl)-4-oxo-1-phenyl-1,4-dihydro-[1,8]naphthyridine-2-carboxylic acid methyl ester 
• 1402345-17-8 3-methoxy-4-{3-[2-(methoxyoxalyl-phenyl-amino)-pyridin-3-yl]-3-oxo-propyl}-benzoic acid methyl ester 
• 1402345-16-7 3-methoxy-4-[3-oxo-3-(2-phenylamino-pyridin-3-yl)-propyl]-benzoic acid methyl ester 

Relevant articles and documents

New Phenol Benzoate Cyanine Picolinium Salt Photoacid Excited-State Proton Transfer

Steady-state and time-resolved fluorescence techniques were employed to study the excited-state proton transfer (ESPT) to water and D2O of a new photoacid, phenol benzoate cyanine picolinium salt (BCyP). We found that the ground-state pKa is about 6.5, whereas the excited-state pKa? is about -4.5. The ESPT rate constant, kPT, to water is ～0.5 × 1012s-1 (τPT ≈ 2 ps) and in D2O the rate is 0.33 × 1012 s-1. We determined that the BCyP photoacid belongs to the third regime of photoacids, the solvent-controlled regime.

Efficient three-component synthesis of diversely substituted tetrahydro-1H-cyclopenta[c]quinolines

The synthesis of highly functionalized substituted tetrahydro-1H-cyclopenta[c]quinoline (I) and its reduced derivatives hexahydro-1H-cyclopenta[c]quinolines (II) via Povarov reaction in high diastereoselectivity and high to moderate yields is described he

NMDA RECEPTOR MODULATORS AND USES RELATED THERETO

This disclosure relates to NMDA modulators and used related thereto such as for treatment of central nervous system disorders. In certain embodiments, compounds disclosed herein are NR2C subunit-selective NMDA potentiators. In certain embodiments, the disclosure contemplates compounds and pharmaceutical compositions. In certain embodiments, the disclosure contemplates compounds disclosed herein as prodrugs, optionally substituted with one or more substituents, derivatives, or salts thereof. In certain embodiments, the disclosure relates to methods of treating or preventing nervous system disorders comprising administering an effective amount of a composition comprising compound disclosed herein to a subject in need thereof.

Design, synthesis, and structure-activity relationship of a novel series of GluN2C-selective potentiators

NMDA receptors are tetrameric complexes composed of GluN1 and GluN2A-D subunits that mediate a slow Ca2+-permeable component of excitatory synaptic transmission. NMDA receptors have been implicated in a wide range of neurological diseases and thus represent an important therapeutic target. We herein describe a novel series of pyrrolidinones that selectively potentiate only NMDA receptors that contain the GluN2C subunit. The most active analogues tested were over 100-fold selective for recombinant GluN2C-containing receptors over GluN2A/B/D-containing NMDA receptors as well as AMPA and kainate receptors. This series represents the first class of allosteric potentiators that are selective for diheteromeric GluN2C-containing NMDA receptors.

SUBSTITUTED HETEROCYCLIC DERIVATIVES

The present invention relates to compounds of general formula (I-1) or (I-2) wherein R1 is hydrogen, lower alkyl, lower alkoxy, halogen, O(CH2)2-lower akoxy, O(CH2)2N(CH3)2, or O(CH2)-morpholinyl; R1' is hydrogen, lower alkyl, lower alkoxy, halogen, O(CH2)2-lower akoxy, O(CH2)2N(CH3)2, or O(CH2)-morpholinyl; with the proviso that both R1 and R1' may be simultaneously hydrogen, but only one of R1 and R1' is lower alkyl, lower alkoxy, halogen, O(CH2)2-lower akoxy, O(CH2)2N(CH3)2, or O(CH2)-morpholinyl; Het is a 5-or 6 membered heteroaryl group, wherein the heteroatom is selected from N, O or S; X is -CRR'-, -CRR'-NR'-, -C(O)-, -CH2-S-, -CH2-S(O)2-, CH2-O- or -CH2-CRR'-; R/R' are independently from each other hydrogen, lower alkyl, hydroxy or phenyl, or R and R' may form together with the carbon atom to which they are attached a cyclopropyl ring; R2 is lower alkyl, -C(O)O-lower alkyl, C3-6-cycloalkyl optionally substituted by lower alkyl or =O, bridged cyclohexyl or C3-6-cycloalkenyl, or is a 5-membered heteroaryl group, wherein the heteroatom is selected from N, O or S and which is optionally substituted by one or more lower alkyl, or is pyridinyl, optionally substituted by halogen or lower alkoxy; or is phenyl, optionally substituted by one or more R2', selected from halogen, cyano, S(O)2-lower alkyl, lower alkyl, lower alkyl substituted by halogen, lower alkoxy, lower alkoxy substituted by halogen or amino, or is benzo[1,3]dioxolyl, naphthyl, indolyl, benzo-isoxazolyl, 2,3-dihydro-1H-indenyl, optionally substituted by lower alkoxy or by an oxo group, or is 3,4-dihydro-2H- [1,4]oxazinyl, optionally substituted by an oxo group, or is a five or six membered heterocycloalkyl group; or to a pharmaceutically acceptable acid addition salt, to a racemic mixture or to its corresponding enantiomer and/or optical isomers thereof. The compounds may be used for the treatment or prophylaxis of schizophrenia, obsessive-compulsive personality disorder, major depression, bipolar disorders, anxiety disorders, normal aging, epilepsy, retinal degeneration, traumatic brain injury, spinal cord injury, post-traumatic stress disorder, panic disorder, Parkinson's disease, dementia, Alzheimer's disease, mild cognitive impairment, chemotherapy-induced cognitive dysfunction, Down syndrome, autism spectrum disorders, hearing loss, tinnitus, spinocerebellar ataxia, amyotrophic lateral sclerosis, multiple sclerosis, Huntington's disease, stroke, radiation therapy, chronic stress, abuse of neuro-active drugs, such as alcohol, opiates, methamphetamine, phencyclidine and cocaine.

SUBSTITUTED TRICYCLIC COMPOUNDS WITH ACTIVITY TOWARDS EP1 RECEPTORS

The present invention belongs to the field of EP1 receptor ligands. More specifically it refers to compounds of general formula (I) having great affinity and selectivity for the EP1 receptor. The invention also refers to the process for their preparation, to their use as medicament for the treatment and/or prophylaxis of diseases or disorders mediated by the EP1 receptor as well as to pharmaceutical compositions comprising them.

ADAMANTYL COMPOUNDS

The invention relates to JNK inhibitors and corresponding methods, formulations, and compositions for inhibiting JNK and treating JNK-mediated disorders. The application discloses JNK inhibitors, as described below in Formula I: wherein the variables are

Biphenyl compounds useful as muscarinic receptor antagonists

The invention provides compounds of formula I: wherein a, b, c, m, s, t, W, Z, Ar, R1, R2, R3, R6, and R7 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.

Biphenyl compounds useful as muscarinic receptor antagonists

This invention provides compounds of formula I: wherein a, b, c, d, m, n, p, s, t, W, Ar1, R1, R2, R3, R4, R6, R7, and R8 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.

FUSED QUINOLINE DERIVATIVE AND USE THEREOF

The present invention aims at provision of a quinoline derivative having a neurokinin 2 (NK2) receptor antagonistic action and relates to a compound represented by the formula (I) wherein Rl is a hydrogen atom and the like; R2 is a hydrogen atom, a hydrocarbon group optionally having substituent(s) and the like; R3 is unsubstituted (i.e., absence), a hydrogen atom and the like; R4 and R5 are the same or different and each is a hydrogen atom, a hydrocarbon group optionally having substituent(s), and the like; R6is (cyclic group optionally having substituent(s)) -carbonyl, and the like; R7, R8,R9 and R10 are the same or different and each is a hydrogen atom, halogen and the like; or R7and R8,R8 and R9,and R9 and R10 may form a ring together with the adjacent carbon atoms; n is an integer of 1 to 5; --- represents unsubstituted (i.e., absence) or a single bond; and --- represents a single bond or a double bond, or a salt thereof, and the like.